Onyx plans phase III trial of ONYX-015 for head & neck cancer.
D000256:Adenoviridae / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D015316:Genetic Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration